AntlerA Leverages Precision-engineered Protein Therapeutic Platform to Harness Body's Regenerative Potential
SAN FRANCISCO, Aug. 27, 2019 /PRNewswire/ -- AntlerA is leveraging a precision-engineered programmable Wnt pathway agonist platform to develop drugs that address large unmet needs in the regenerative medicine area. AntlerA's technology platform is based on a decade long research activity conducted